News

Greciet will succeed Dominique Costantini, co-foundator and CEO of BioAlliance Pharma. She is working as the chief operating officer of the company since 1 March 2011. Greciet has

The milestone triggers from the initiation of a Phase I clinical trial of an experimental compound by Boehringer Ingelheim for the treatment neuropathic pain. Previously, Evotec had entered

Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. The study showed reduction in HbA1c versus placebo for

Nimotuzumab, a humanized monoclonal antibody targeting EGFR, is indicated for the patients with brain metastasis from non-small cell lung cancer (NSCLC) and palliative treatment of NSCLC. YM BioSciences

RFID Wristbands, known as IC-BANDs, are made of Tyvek material and are available in many colors. RFID Wristbands are used in applications such as cashless payment tracking, tracking

Developed by discovered by D-Pharm, DP-VPA is a drug indicated for the treatment of patients who are suffering from epilepsy, migraine and bipolar disorder. As per the terms

In the trial, the drug was well tolerated at all the doses tested and has demonstrated preliminary evidence of efficacy. The trial investigated the safety, tolerability and efficacy

Earlier, the company has received orphan drug status for CYT387 for the treatment of myelofibrosis from the US Food and Drug Administration (FDA). YM BioSciences president and CEO

As per the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of US patent 7,935,528. The patent covers the methods